Abstract: The invention is directed to physiologically active compounds of general formula (I): 1

Abstract: The invention is directed to physiologically active compounds of general formula (I): 1

Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).

Abstract: This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

Abstract: This invention is directed to 1-alkoxy-2-(alkoxy- or cycloalkyloxy-)-4-(cyclothioalkyl- or cyclothioalkenyl-)benzene compounds that inhibit cyclic AMP phosphodiesterase or tumor necrosis factor (TNF) and are useful in treating patients suffering from disease state capable of being modulated by inhibiting production of cyclic AMP phosphodiesterase or TNF by administering the compound to the patient. The invention is also directed to the preparation of these compounds, pharmaceutical compositions containing these compounds and methods for their pharmaceutical use.

Abstract: Therapeutically useful isoquinolinone derivatives of the formula A--X--R.sup.3, wherein A represents a group of the formula: ##STR1## wherein R.sup.1 and R.sup.2 represents cycloalkyl, alkyl, alkenyl or alkynyl optionally substituted by halogen or cycloalkyl, or represents optionally substituted aryl or heteroaryl, R.sup.4 represents hydrogen, halogen, optionally substituted alkyl, alkenyl or alkynyl, optionally substituted aryl or heteroaryl, or a group R.sup.6 O-- wherein R.sup.6 represents alkyl, aryl or arylalkyl, X represents ethylene or vinylene, R.sup.3 represents a group of the formula:--Y.sup.1 --CH.sub.2 --CH(OH)--CH.sub.2 --COOR.sup.5wherein Y.sup.1 represents carbonyl, hydroxymethylene or --C(OR).sub.2 -- wherein R represents alkyl or the two R symbols together represent alkylene and R.sup.5 represents hydrogen or optionally substituted alkyl or R.sup.

Abstract: Therapeutically useful pyrrolo[2,1-a]phthalazine derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2 represent cycloalkyl, optionally substituted alkyl, alkenyl, alkynyl, aryl or heteroaryl, X represents ethylene or vinylene, R.sup.3 represents a group of the formula:--Y--CH.sub.2 --CH(OH)--CH.sub.2 --COOR.sup.5wherein Y represents carbonyl or hydroxymethylene and R.sup.5 represents hydrogen or optionally substituted alkyl, or R.sup.3 represents a lactone ring and the symbols R.sup.4 represent hydrogen, halogen, optionally substituted alkyl, alkenyl, alkynyl, aryl or heteroaryl, or R.sup.6 O-- wherein R.sup.6 represents alkyl, aryl or arylalkyl and salts thereof, processes for their preparation and compositions containing them are described.

Abstract: Pyrrolo[2,1-a]isoquinoline derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2 each represent cycloalkyl or alkyl, alkenyl or alkynyl which may be halogen-substituted, or optionally substituted aryl or heteroaryl, X represents ethylene or vinylene, R.sup.3 represents a group of the formula:--Y--CH.sub.2 --CH(OH)--CH.sub.2 --COOR.sup.5 IIwherein Y represents carbonyl or hydroxymethylene and R.sup.5 represents hydrogen or optionally substituted alkyl, or R.sup.3 represents a lactone ring, and the symbols R.sup.4 represent hydrogen, halogen, optionally substituted alkyl, alkenyl or alkynyl, optionally substituted aryl or heteroaryl, or a group of the formula R.sup.6 O--, wherein R.sup.6 represents alkyl, aryl or arylalkyl and pharmaceutical properties.

Abstract: Indole and indoline derivatives of the formula: ##STR1## wherein indicates a double bond or a single bond between carbon atoms, R.sup.1 represents hydrogen, alkyl of 1 through 6 carbon atoms, or alkyl of 1 through 6 carbon atoms substituted by one or more than one of the same type of substituents selected from the hydroxy group, alkenyl groups of 2 through 5 carbon atoms, and alkanoyloxy groups of 2 through 7 carbon atoms, and one of the symbols R.sup.2 represents alkyl of 6 through 24 carbon atoms and the other symbol R.sup.2 represents alkyl of 1 through 24 carbon atoms or hydrogen, and R.sup.3 represents alkyl of 1 through 6 carbon atoms or hydrogen, are new compounds possessing useful pharmacological properties. They are of use in the treatment of diabetes mellitus, hyperlipoproteinaemic states, of atherosclerosis, and of associated conditions.